Rakovina Therapeutics Inc (V:RKV) — Market Cap & Net Worth
Market Cap & Net Worth: Rakovina Therapeutics Inc (RKV)
Rakovina Therapeutics Inc (V:RKV) has a market capitalization of $2.14 Million (CA$2.96 Million) as of May 26, 2026. Listed on the V stock exchange, this Canada-based company holds position #29818 globally and #1495 in its home market, demonstrating a 40.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rakovina Therapeutics Inc's stock price CA$0.14 by its total outstanding shares 21148039 (21.15 Million). Analyse RKV cash generation efficiency to see how efficiently the company converts income to cash.
Rakovina Therapeutics Inc Market Cap History: 2021 to 2026
Rakovina Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $3.37 Million to $2.14 Million (-10.66% CAGR).
Rakovina Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rakovina Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RKV by Market Capitalization
Companies near Rakovina Therapeutics Inc in the global market cap rankings as of May 26, 2026.
Key companies related to Rakovina Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.28 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #417 globally with a market cap of $65.82 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #579 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #599 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.28 Billion | $434.52 |
| #417 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $65.82 Billion | $638.88 |
| #579 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #599 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Rakovina Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Rakovina Therapeutics Inc's market cap moved from $3.37 Million to $ 2.14 Million, with a yearly change of -10.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$2.14 Million | +40.00% |
| 2025 | CA$1.53 Million | -47.37% |
| 2024 | CA$2.91 Million | +123.53% |
| 2023 | CA$1.30 Million | -52.78% |
| 2022 | CA$2.75 Million | -18.18% |
| 2021 | CA$3.37 Million | -- |
End of Day Market Cap According to Different Sources
On May 25th, 2026 the market cap of Rakovina Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.14 Million USD |
| MoneyControl | $2.14 Million USD |
| MarketWatch | $2.14 Million USD |
| marketcap.company | $2.14 Million USD |
| Reuters | $2.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more